Washington University School of Medicine
St Louis, Missouri, 63110, United States
NCT Number: NCT02994459
People who are obese often have insulin resistance (inability of insulin to properly control blood sugar) and high blood sugar. However, not all people with obesity have this problem. About one-third of people with obesity have normal sugar metabolism (the way your body uses sugar). Similarly, not all people who are lean are also metabolically healthy and a subset of people who are lean are referred to as metabolically abnormal lean (MAL) or metabolically obese lean because they have the abnormalities in glucose metabolism typically associated with obesity. The reasons why some people with obesity have a problem with blood sugar control and others do not are not entirely clear. It is thought that impaired muscle sugar uptake is the main problem related to high blood sugar in people with obesity. However, adipose tissue (fat tissue) also consumes a substantial amount of blood sugar. Therefore, it is unclear whether muscle or adipose tissue (fat tissue) are primarily responsible for altered blood sugar concentrations in persons with metabolically abnormal obesity (MAO) (those with insulin resistance), compared to those with metabolically normal (healthy) obesity (MNO), or whether "healthy" adipose tissue (fat tissue) expansion in MNO people compared with lean people provides a vessel for blood sugar removal that helps maintain normal blood sugar concentration.
Accordingly, the investigators will determine the amount of sugar that is taken up by the body and in the cells of adipose tissue (fat tissue) and muscle by infusing labeled sugar into the blood and looking at its disappearance from blood and appearance in adipose tissue (fat tissue) and muscle. The investigators will also determine how well insulin, a hormone that controls blood sugar, turns on signals that stimulate sugar uptake in fat and muscle cells. These studies will be done after an overnight fast and during an infusion of sugar and insulin (hyperinsulinemic-euglycemic clamp), in sex- and age-matched people who are insulin resistant and insulin sensitive. People with obesity will also be invited to complete a ~10% diet-induced weight loss program and will be studied again after they have achieved the weight loss goal. A group of sex- and age-matched metabolically normal lean participants will serve as control group. An attempt will be made to also study a group of sex- and age-matched metabolically abnormal lean participants.
This study is active but is not currently recruiting participants.
18 year–64 year
All sexes
Observational
St Louis, Missouri, 63110, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
All subjects
In addition, subjects must fulfill all of the following inclusion criteria.
Metabolically Normal Lean
Metabolically Normal Obese, likely insulin sensitive
Metabolically Abnormal Obese, likely insulin resistant
Metabolically Abnormal Lean
Diet-induced weight loss (obese only)
Time frame: Baseline
Comparison of whole body and total adipose tissue glucose disposal rate assessed by using stable isotope labeled glucose tracer infusion in conjunction with dynamic PET imaging
University of Missouri-Columbia
Other
Adipose Tissue Glucose Uptake in Obesity (ATGD)
Acronym: ATGD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02710370
Body Weight, Diabetes Mellitus
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06295640
Glucose Metabolism Disorders, Hyperinsulinism
Ulm, Germany
View Trial DetailsNCT04972955
Diabetes Mellitus, Diabetes Mellitus, Type 2
Calgary, Alberta, Canada
View Trial DetailsNCT05445284
Autoimmune Diseases, Diabetes Mellitus
Montreal, Quebec, Canada
View Trial Details